Evidence map›Paper›PMID 23856289›Full record

ReviewBiochemical pharmacology2013

Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia.

Jared W Young, Mark A Geyer

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biochemical pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed, 1 pooled it
10.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 1 synthesis or guideline pooled it, 125 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Jared W YoungDepartment of Psychiatry, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0804, United States; Research Service, San Diego Veteran's Affairs Hospital, 3350 La Jolla Drive, San Diego, CA 92037, United States. Electronic address: jaredyoung@ucsd.edu.
Mark A Geyer
University of California, San Diego · US

Funding

SENSORY GATING &HABITUATION IN SCHIZOPHRENIAR01MH042228 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BRAFF, DAVID L. · 1987 to 2015
$6.5M
Inhibitory Deficits in Mania and Hyperdopaminiergic MiceR01MH071916 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GEYER, MARK A, PERRY, WILLIAM · 2004 to 2014
$4.2M
NIMH NIH HHS R01 MH042228NIMH NIH HHS R01-MH04228NIMH NIH HHS R01 MH071916NIMH NIH HHS R01-MH071916
6 · The paper itself

Abstract

The group of schizophrenia disorders affects approximately 1% of the population and has both genetic and environmental etiologies. Sufferers report various behavioral abnormalities including hallucinations and delusions (positive symptoms), reduced joy and amotivation (negative symptoms), plus inattention and poor learning (cognitive deficits). Despite the heterogeneous symptoms experienced, most patients smoke. The self-medication hypothesis posits that patients smoke to alleviate symptoms, consistent with evidence for nicotine-induced enhancement of cognition. While nicotine acts on multiple nicotinic acetylcholine receptors (nAChRs), the primary target of research is often the homomeric α7 nAChR. Given genetic linkages between schizophrenia and this receptor, its association with P50 sensory gating deficits, and its reduced expression in post-mortem brains, many have attempted to develop α7 nAChR ligands for treating schizophrenia. Recent evidence that ligands can be orthosteric agonists or positive allosteric modulators (PAMs) has revitalized the hope for treatment discovery. Herein, we present evidence regarding: (1) pathophysiological alterations of α7 nAChRs that might occur in patients; (2) mechanistic evidence for the normal action of α7 nAChRs; (3) preclinical studies using α7 nAChR orthosteric agonists and type I/II PAMs; and (4) where successful translational testing has occurred for particular compounds, detailing what is still required. We report that the accumulating evidence is positive, but that greater work is required using positron emission tomography to understand current alterations in α7 nAChR expression and their relationship to symptoms. Finally, cross-species behavioral tasks should be used more regularly to determine the predictive efficacy of treatments.

Indexed as

alpha7 Nicotinic Acetylcholine ReceptorAntipsychotic AgentsDopamineHumansSchizophreniaalpha7 Nicotinic Acetylcholine ReceptorAntipsychotic AgentsDopamineCognitionPositron emission tomographyTranslational research

Identifiers

PMID23856289
PMCPMC3797190
OpenAlexW2057320515

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.